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T
 
he goal of this panel was to identify key issues
in the application of healthcare intervention
economic evaluations in healthcare decision-mak-
ing. Its specific objectives were to:
• identify and prioritize the key issues associated
with using healthcare economic intervention in
healthcare decision-making;
• identify a plan of action to resolve these issues;
• recommend next steps.
 
Background and Context
 
The last 12 to 15 years has witnessed a rapid
growth of health economics and outcomes re-
search. This growth has been largely propelled by
competitive pressures within the healthcare indus-
try, which created a need among healthcare deci-
sion-makers for methods that would allow them
to contrast and compare the costs and conse-
quences of healthcare interventions. Pharmaceuti-
cal product selection has become a key area for
use of economic studies.
Formulary decision-makers using the results of
economic studies and models can be categorized
into three groups:
1. Healthcare decision-makers in practice set-
tings use health economic and outcomes in-
formation in drug selection for formularies.
There are currently over 8000 hospital and
managed care organizations in the United
States that frequently make drug-selecting de-
cisions for formulary inclusion.
2. Policy-makers within state and federal agen-
cies are required to assist in evaluating pre-
scription drug coverage decisions for various
programs, or use health economic informa-
tion to construct policy.
3. Development managers within the pharma-
ceutical industry who have a growing need to
increase the return on investment in research
and development.
In current market dynamics, drug choice deci-
sions are made or driven by various stakeholders,
including pharmacy and therapeutics (P&T) com-
mittees of hospitals and health plans, drug pur-
chasers for large employers or buying groups,
government bodies, practicing physicians, retail
pharmacists, insurance companies, pharmacy ben-
efit management companies, and patients. Drug
choice decisions are made most often on the basis
of clinical efficacy and safety information, without
knowledge of the impact on total cost to a health-
care system. Groups making these decisions gener-
ally have little background in the issues of health
economics and outcomes research.
Currently, health economic information is of-
ten delivered to decision-makers through the phar-
maceutical industry or their representatives (i.e.,
consultants, research organizations, and acade-
mia) in support of a particular drug therapy or
specific drug choices. There is not much consis-
tency in how this information is offered, since
each company and each researcher may present a
different view of the research and the results. As a
result, health economic studies are viewed skepti-
cally and as having limited applicability in the
process of drug choice decision-making. Although
this has improved recently, surveys of decision-
makers and comments by practitioners on the
value and relevance of health economic informa-
tion and reports do not yet indicate a compelling
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demand from decision-makers for economic and
outcome evaluative information [1–5].
 
Problem Statement
 
Information about the impact of new therapies on
costs within a healthcare system should be essen-
tial for making better healthcare decisions. How-
ever, the relevance of health economic information
to decision-makers has not been demonstrated.
There is little user-friendliness in the health eco-
nomic data supplied by industry consultants.
Moreover, there is a lack of consistency of ap-
proach and format that would facilitate compari-
son of pharmaceuticals under review. Finally,
much of the information presented lacks the trans-
parency necessary for the user to determine the
appropriateness of methods or the soundness of
assumptions.
 
Issues
 
A fundamental disconnect exists between (1) the
way decisions are made by healthcare decision-
makers, (2) the type of information presented to
healthcare decision-makers, and (3) the type of in-
formation produced by health economic and out-
comes researchers. Eleven key issues are:
1. Evaluative criteria perspective: Evaluative cri-
teria (e.g., efficacy, safety, cost, quality of life)
are often weighed differently by potential users
of health economic research data for decision-
making purposes such as formulary commit-
tees, providers, health plan managers, patients,
or employers.
2. Language and definitional barriers: Language
and definitional barriers hinder effective com-
munication between potential users and pro-
ducers of the information.
3. Lack of treatment comparisons: There is little
data on direct product or treatment compari-
sons that are of greatest interest to potential
users.
4. Lack of communication: Little dialogue exists
between the potential users and the producers
of information on what is relevant and what
information can be generated by health eco-
nomic research.
5. Lack of understanding: Potential users of health
economic research data may be hesitant to in-
clude health economic information in their
decision-making process because it is different
from their established clinical orientation.
6. Conflicting study design: To conduct studies
that provide health economic information that
meets users’ needs, certain research designs
for health economic and outcomes research
studies may conflict with clinical design, caus-
ing regulatory and liability concerns.
7. Research funding: Some sources of research
funding may present a barrier to the credibil-
ity and application of study results.
8. Societal perspective versus individual perspec-
tive: A conflict may exist between recommen-
dations based on population data and the care
of individual patients.
9. Lack of quality criteria: When health eco-
nomic research data is used in the decision-
making process, there is no recognized ap-
proach for measuring the quality of the deci-
sion or the net result.
10. Lack of experts: There are few skilled opinion
leaders or other resources from which poten-
tial users can seek advice and assistance.
11. Segregation of organizational finances and
health outcome decisions: Decision-maker or-
ganizations segregate budgetary decisions for
pharmaceuticals from those related to other
medical technologies and services.
 
Evaluative Criteria Perspective
 
Decision-makers often weigh evaluative criteria
differently. One barrier to the use of health eco-
nomic studies is that multiple decision-makers
weigh criteria differently. For example, patients
may place a different importance on certain qual-
ity-of-life attributes of a product than the physi-
cians prescribing it or the managed care decision-
makers providing access to the product in their
plan. Even within categories of decision-makers,
variability in the weight placed on attributes ex-
ists. Taking this a step further, decisions that are
optimal from society’s perspective may be unac-
ceptable from the perspective of an individual plan
or patient. As a result, health economic studies
that attempt to construct a single metric may en-
counter resistance from decision-makers. The Panel
on Cost-Effectiveness in Health and Medicine [6]
has recommended conducting “reference case”
cost-effectiveness analysis from the societal per-
spective as a way of enhancing comparability
across studies, as well as from other perspectives
that are relevant to the decision at hand.
 
Language and Definitional Barriers
 
Language and definitional barriers exist that pre-
vent the effective communication between users
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and suppliers of health economic information. Sci-
entific jargon may hinder effective communication
between the producer and the end-user of health
economic information. A major problem is in defi-
nition of terms. For example, “cost-effectiveness
analysis” has been confused by some as meaning
only “cost-saving” or “cost-reducing,” whereas in
practice the term describes the jointly determined
relationship between outcomes of competing ther-
apies measured in terms of effectiveness and the
costs required to achieve that level of effectiveness.
Cost-savings is only one possible result. Other
terms such as cost-utility, quality-adjusted surviv-
al, healthy-year equivalents, Gompertz functions,
bootstrap, and time preference hold very little
meaning to the practicing physician, the pharma-
cist, or the health plan manager. Thus, when eco-
nomic and outcomes data or models are provided
to clinically oriented individuals for the purpose
of formulary consideration, some or most of the
message may be lost simply because of these lan-
guage barriers.
Researchers in the field of health economics
may propagate some confusion by coining terms
in an attempt to clarify methods to peers that gen-
erates confusion for those outside the field. This
nomenclature distances the field, the publications,
and the potential application of results from the
user. If it is to be useful, there is a need for educat-
ing the user to better understand this information.
There is an even greater need on the part of the in-
formation producers to provide economic and
outcomes messages that are clear, precise, rele-
vant, and containing no unnecessary jargon.
 
Lack of Treatment Comparisons
 
Available information fails to provide data on di-
rect product or treatment comparisons that are of
greatest interest to potential users. Head to head
comparisons of performance in multiple dimen-
sions of competing drugs, not just cost of the prod-
uct, is information critical to committees making
formulary decisions. For this type of user, com-
parison of one drug to another may be of primary
concern; to other users, such as practicing physi-
cians and patients, these comparisons must look at
alternatives beyond drug choices. Physicians are
making treatment decisions with increasing input
from patients. These decisions are not limited to
drug choices. They include no treatment, non-
pharmaceutical alternatives such as diet changes,
therapy, or surgery, and other treatment options
such as homeopathic remedies.
 
Inadequate Dialogue
 
Little dialogue exists between users and suppliers
of health economic information on what is rele-
vant and what can be generated. A multitude of
guidelines to health economic research, some of
which give conflicting guidance, exist in the
United States and elsewhere. Healthcare decision-
makers, or their consultants, may choose any
of these guidelines. Inconsistent decision-making
within or between organizations may result. In ad-
dition, within the time frame of current decision-
making, many of these guidelines are too complex
and time consuming to be a realistic part of deci-
sion-making for either the user or the supplier of
the information. The pharmaceutical industry has
provided information in response to a global re-
quest for economic data to support healthcare de-
cisions. However, the information is not being used
or used appropriately. This behavior indicates a
need for clarification by the decision-maker about
specifically what information is needed, and by the
researcher what information can be provided. Con-
versely, suppliers of information have not been pro-
active in seeking to assist users in making decisions.
For example, market research data developed for
internal product decisions could be very helpful to
healthcare decision-makers.
 
Lack of Understanding
 
Potential users of health economic and outcomes
research data may be hesitant to include health
economic information in their decision-making
process because it is different from their estab-
lished clinical orientation. Decisions regarding use
of and coverage for pharmaceuticals are usually
placed with committees of clinically trained pro-
fessionals, such as physicians, pharmacists, and
nurses whose training focuses their attention on
pharmacological and therapeutic aspects of treat-
ments. They usually have little background to sup-
port the incorporation of different types of valu-
ing schemes, such as health economic research,
into their decisions.
Additionally, federal drug approval regulations
require that manufacturers generate evidence of
product efficacy and safety through the use of
specified research methods. Decision-making bod-
ies have readily adopted the use of efficacy and
safety data into their deliberations since it coin-
cides with the clinical aspects of their training. In-
corporating information from outside a well-devel-
oped decision-making paradigm is difficult. When
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the existing paradigm is complex, the implications
for incorrect decisions are significant. Decision-
makers may not feel comfortable with changes to
an established process.
 
Conflicting Study Design
 
Regulatory and liability concerns may conflict
with certain research designs for health economic
and outcomes research studies that meet decision-
maker needs. An often-noted problem in develop-
ing information for formulary decisions is the
timing of drug approvals and the need for com-
parative information. Drug companies have the
responsibility of gathering data to support drug
approvals. However, companies also want to pro-
vide useful outcomes information about their
products at the time of product launch, when for-
mularies make initial purchase decisions. Formular-
ies often request comparative information derived
from studies in populations and settings with simi-
lar characteristics to the purchasing group.
One solution for this dual set of interests would
be for drug companies to perform phase III studies
that could be used for both regulatory and mar-
keting purposes. Often humanistic and resource
utilization data may be gathered as “add-ons” to
existing protocols. However, certain regulatory
requirements may make it difficult to create valid
designs for outcome studies. For example, safety
concerns may make it necessary for protocol plan-
ners to include physician visits, physical examina-
tions, and laboratory tests at more frequent inter-
vals than would be utilized in routine practice.
These planned visits and tests may make it impossi-
ble to assess whether study drugs variably caused
unscheduled and extra physician visits. Similarly,
patient management concerns at managed care or-
ganizations may make it difficult to plan valid
clinical studies. They may have policies that pro-
hibit the use of placebos, random assignment of
patients to treatment, or other design features es-
sential to the conduct of a clinical trial. Managed
care organizations may also be unwilling to fund
certain data collection costs, or their accounting
system may require them to charge all of the costs
necessary to treat patients enrolled in the trial,
even costs not related to the trial, to the funding
agent.
 
Research Funding
 
The source of research funding may present a bar-
rier to the credibility and application of study re-
sults. Many health economic studies are currently
funded by the pharmaceutical industry, either di-
rectly or indirectly through persons contracted to
do such research, for example, consultants, re-
search organizations, or academia. This has led to
serious concerns by potential users of the informa-
tion that it is biased towards the sponsoring com-
pany’s product and therefore lacks credibility.
In light of the fact that decision-makers at man-
aged care organizations have complained about
the lack of independence of health economic re-
search studies, it is curious that they have not
funded more studies themselves. Only rarely have
some plans paid for studies, directly or indirectly,
by sponsoring research conducted by independent
groups or consultants. This may reflect their lack
of familiarity with health economic research tech-
niques or it may be that plans cannot capture for
themselves the full return on investment when
sponsoring the information.
 
Societal Perspective versus Individual Perspective
 
A conflict exists between recommendations based
on population data and care of individual pa-
tients. By definition, health economic analysis is
population based. Decisions about drug alterna-
tives using health economic data inherently con-
sider optimization of resource use relative to out-
comes across populations. These decisions are
made using the values of the decision-makers ap-
plied to larger groups, which may not coincide
with the values of individual patients or physi-
cians, especially when the economic issues consid-
ered do not directly apply to them. Patients are
generally unmoved by physician or health plan ex-
planations that their drug- or treatment-of-choice
is not available to them because it is not “cost-
effective.”
This debate about optimization of health for
populations versus individuals is far from resolu-
tion in the United States. Without an agreed-upon
values framework that will stand up to scrutiny by
all users, decision-makers will continue to struggle
to defend decisions, not just drug choice, that are
in any way driven by a trade-off between popula-
tion health costs against individual outcomes.
 
Lack of Quality Criteria
 
There is no measurement system to validate deci-
sions. Health economic research is designed to in-
form choices among alternative medical technolo-
gies. In the most complex situation, a study may
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find that a certain relatively costly new therapeutic
product offers more “value” to the adopting orga-
nization than the current less expensive therapy.
“Value” may be defined using an abstract metric
such as quality-adjusted life-years.
Once an organization has adopted a new tech-
nology, some implications of the decision may be
readily visible. For example, pharmacy expendi-
tures may have increased. But whether or not
“value” has also increased may not be so readily
discernible. While the potential consumers of health
economic research, such as managed care organiza-
tions, have in place mechanisms to track resource
utilization (cost) they generally lack comparable
procedures for quantifying outcomes of care (ef-
fect).
 
Lack of Experts
 
There is an inadequate availability of opinion-
leaders to turn to for assistance. For the end-users
of health economic analysis, interpretation of a
study can represent a formidable task. Methods
and findings are typically described using the jar-
gon that characterizes any specialized field. Ana-
lytic methodology may be complex, and is becom-
ing more so as researchers adopt techniques such
as calculation of confidence intervals around cost-
effectiveness ratios.
The availability of published checklists to eval-
uate the quality of a study can facilitate review by
persons with somewhat limited expertise. How-
ever, a study that appears to conform to recog-
nized standards may still be seriously flawed. In
part, this is due to the widespread dissemination
of guidelines for health economic research. These
guidelines are effectively creating templates for
study presentation.
Many end-users lack internal expertise to assess
the validity and reliability of health economic
studies. In such a situation it would be natural to
seek outside advice; however, this is not easy to
locate. End-users may not be aware of mentors,
individuals, or organizations such as academic
groups or consultants, that could offer guidance,
and there is no formal mechanism for identifying
such expertise or referring end-users to potential
advisors.
 
Segregation of Organizational Finances and Health 
Outcomes Decisions
 
Decision-maker organizations segregate budgetary
decisions for pharmaceuticals from those related
to other medical technologies and services. Man-
aged care organizations and hospitals most often
have separate budgets managed by separate de-
partments for pharmaceuticals versus other medi-
cal technologies and services. This separation
places downward pressure on both budgets sepa-
rately and creates difficulty for efforts that at-
tempt to assess the budgetary impact of individual
pharmaceutical therapies on the entire medical
cost budget. This silo effect is a significant impedi-
ment to better utilization of pharmacoeconomic
and outcomes information in decision-making.
 
Recommendations and Next Steps
 
For the following recommendations to become a re-
ality, a central organizer must be recruited to coordi-
nate the improvement of the application of health-
care intervention economic evaluations in healthcare
decision-making. The International Society for Phar-
macoeconomic and Outcomes Research (ISPOR),
as a recognized leading international organization
in the field of health economics, is proposed as the
critical link to implementing these recommenda-
tions.
• To determine the information needs of the
community, ISPOR-sponsored focus groups
should be created to provide a forum for dia-
logue between potential users, producers, and
regulators of information. Researchers and
suppliers of health economic data must ac-
tively engage with decision-makers to determine
the key health economic evaluative criteria for
decision-making purposes and formulate ways
to supply the information consistently. Because
decisions are seldom made using a single vari-
able, determining a set of variables that re-
searchers can supply will move the discipline
toward greater relevance. A multivariable ap-
proach will allow the decision-makers flexibil-
ity to focus on evaluative criteria germane to
their population while providing researchers
the opportunity to highlight key criteria on
which a product excels or falls short. To estab-
lish the needed relevance, cooperation among
users and researchers, both industry and aca-
demic, is essential.
• ISPOR should develop a set of simple criteria
for evaluation of these studies, agreed upon by
consensus of all parties involved, and designed
to recognize different types of perspectives and
research design so that specified research ques-
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tions and business needs are met. ISPOR
should also seek to bolster the objectivity, reli-
ability, and credibility of the health economic
studies through various mechanisms, including
working with sponsors, researchers, and jour-
nal editors, to adopt protocols that will estab-
lish the independence of research and state-
ments for the disclosure of funding sources.
• A training initiative for decision-makers in
using health economic research information
for decision-making can be offered through
ISPOR. Educational programs in the area of
health economic analyses should be created for
clinically trained decision-makers. The focus
may be directed towards how health economic
information can be incorporated into existing de-
cision-making paradigms, and the added value
that health economic data can provide in deci-
sion-making. A consortium of managed care
and other purchasing organizations, academic
researchers, and one or more health economic
research organizations should be formed to exe-
cute this recommendation. Funding to support
the effort should come from pharmaceutical in-
dustry, government, and, to the extent possible,
managed care and other purchasing organiza-
tions that wish to participate. The project should
be conducted over a 2-year education period
with a 2-year follow-up evaluation. The educa-
tion program itself should continue until the re-
sults of the 2-year evaluation are completed.
Suggested criteria for project evaluation
could include: (1) interviews with decision-
makers regarding changes in their decision
analysis process; (2) impressions as to how the
decisions have been changed; (3) longer term
analysis of the impact on healthcare resource
allocation and on patient health within the
participating healthcare systems.
• A standard reporting format to allow flexible
weighting of factors based on individual deci-
sion-making preferences should be developed
by ISPOR in collaboration with potential users
and producers of information. It is suggested
that presentation of the results of health eco-
nomic analyses be modified to show the vari-
ous components of effectiveness measures, ser-
vice utilization measures and costs. This way
clinically oriented decision-makers can observe
similarities of information between what they
currently use and that used in health economic
analyses. A standard approach to providing
clinical, economic and outcomes data to deci-
sion-makers should be developed to minimize
use of technical jargon and effectively commu-
nicate the necessary data and results. Coinci-
dent with an effort to train the user commu-
nity in language and methodology of economic
evaluation and outcomes research (as in rec-
ommendation 2), this would reduce the lan-
guage gap between the producer and consumer
of healthcare economic information.
• ISPOR should form a committee that would
produce a standard format for Data Element
Shells (DESs). DESs would be in the form of
desegregated data from cost-consequence or
cost-effectiveness analyses. For each outcome
of interest, reference to the data source could
be made to allow reviewers to discern the de-
gree of scientific support for each data ele-
ment. The information presented would be
based upon feedback from managed care orga-
nization purchasing agents about the types of
information needed to make purchasing deci-
sions (as in recommendation 1). This type of
cost-consequence information would be pro-
vided in addition to full cost-effectiveness anal-
yses. It would permit purchasers to understand
the effects of drugs that are being considered
on the outcomes of greatest relevance to the in-
dividual groups. Drug companies would be
free to present additional information on out-
comes. Managed care organizations could eas-
ily compare the results of several competing
CEAs with the use of a standardized format.
Areas where data was not available would be
evident. ISPOR, in collaboration with poten-
tial users and producers of information, could
be responsible for creation of and updates to a
DES form. The ISPOR committee would de-
cide on the level of specificity of the DES, per-
haps either a general format for all drugs or a
specific format for individual drug classes.
• ISPOR should support an information clear-
inghouse of available thought-leaders and ex-
perts in the field. This should include develop-
ment and maintenance of an Internet Web site
with links to expert’s homepages and email ad-
dresses. ISPOR as an organization brings to-
gether many of the researchers qualified to
evaluate health economic research and inter-
pret findings. ISPOR could develop rosters of
persons qualified to review studies, similar to
editorial boards for journals, where the re-
viewers would agree to participate in review-
ing documents or addressing queries to pro-
mote a better understanding of the field of
healthcare economics.
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Summary
 
Applying the knowledge provided by health eco-
nomic studies to healthcare decisions at all levels
can only be an asset to healthcare systems. To
achieve this, it is paramount that the information
needs of potential users of health economics be
determined, that training is provided to facilitate
better use of this information, and that the results
of health economic studies be presented in an eas-
ily interpreted and comparable way. Allowing us-
ers of this information access to experts in the
field when additional support is needed will
ensure that the information is not dismissed be-
cause it is not understood. A relevant association
such as ISPOR has been proposed as a facilitator,
bringing representatives of drug companies, man-
aged care organizations, and regulatory agencies
together to discuss areas of compromise, which
will allow performance of more efficient and use-
ful studies. ISPOR should also participate in the
design and funding of educational programs and
in the development of standardized data reporting
formats.
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